Lymphoma News

Since the approval of the first chimeric antigen receptor T-cell therapy, the research community has grappled with a crucial question.

Researchers from Europe and the U.S. developed a hematologic toxicity score that can predict which patients are more likely to develop severe infections after chimeric antigen receptor T-cell therapy.

The FDA cleared investigational new drug applications for three cell therapies in development for oncology indications.

Septic shock remained significantly associated with increased 28-day mortality among patients with hematologic malignancies, according to study results published in Journal of the National Comprehensive Cancer Network.

Faith E. Davies, MD, has been appointed the inaugural director of Center for Blood Cancers at NYU Langone Health’s Perlmutter Cancer Center.

The addition of brentuximab vedotin to front-line chemotherapy reduced risk for death by 41% among patients with newly diagnosed advanced classical Hodgkin lymphoma, according to topline data released by the agent’s manufacturer.

The FDA is investigating a possible increased mortality risk with umbralisib, approved in the United States for treatment of two types of lymphoma.

President Joe Biden has unfinished business with cancer.

The FDA updated the prescribing information for axicabtagene ciloleucel to allow the use of prophylactic corticosteroids to manage the severity of certain treatment-related adverse events.

Patients with rheumatoid arthritis who received tofacitinib demonstrated a greater risk for major adverse cardiovascular events and cancer than those treated with TNF inhibitors, according to data in The New England Journal of Medicine.